Session

PP 05 IBD (Posters)

THE IMPACT OF COVID-19 ON THE THERAPEUTIC DECISIONS AND MONITORING OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A RETROSPECTIVE SINGLE-CENTER STUDY
THE IMPACT OF COVID-19 ON THE THERAPEUTIC DECISIONS AND MONITORING OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A RETROSPECTIVE SINGLE-CENTER STUDY

PP 05 IBD (Posters)  et al.

MICROSCOPIC COLITIS AND RISK OF INCIDENT ACUTE PANCREATITIS: A NATIONWIDE POPULATION-BASED MATCHED COHORT STUDY
MICROSCOPIC COLITIS AND RISK OF INCIDENT ACUTE PANCREATITIS: A NATIONWIDE POPULATION-BASED MATCHED COHORT STUDY

PP 05 IBD (Posters)  et al.

PREDICTORS OF RELAPSE IN CASES OF ULCERATIVE COLITIS THAT ACHIEVED MUCOSAL HEALING WITH BIOLOGICS
PREDICTORS OF RELAPSE IN CASES OF ULCERATIVE COLITIS THAT ACHIEVED MUCOSAL HEALING WITH BIOLOGICS

PP 05 IBD (Posters)  et al.

ISOLATED ANASTOMOTIC LINE ULCERATIONS ARE ASSOCIATED WITH A HIGHER RISK OF POSTOPERATIVE RECURRENCE IN PATIENTS WITH CROHN’S DISEASE UNDERGOING ILEOCECAL RESECTION AND A DIFFERENTIAL MUCOSA-ASSOCIATED MICROBIOME COMPOSITION
ISOLATED ANASTOMOTIC LINE ULCERATIONS ARE ASSOCIATED WITH A HIGHER RISK OF POSTOPERATIVE RECURRENCE IN PATIENTS WITH CROHN’S DISEASE UNDERGOING ILEOCECAL RESECTION AND A DIFFERENTIAL MUCOSA-ASSOCIATED MICROBIOME COMPOSITION

PP 05 IBD (Posters)  et al.

THE COMPARATIVE EFFECTIVENESS OF VEDOLIZUMAB IN BIO-NAÏVE AND BIO-EXPERIENCED PATIENTS WITH IBD: RESULTS FROM A REAL-WORLD EXPERIENCE AT A BELGIAN TERTIARY CENTRE
THE COMPARATIVE EFFECTIVENESS OF VEDOLIZUMAB IN BIO-NAÏVE AND BIO-EXPERIENCED PATIENTS WITH IBD: RESULTS FROM A REAL-WORLD EXPERIENCE AT A BELGIAN TERTIARY CENTRE

PP 05 IBD (Posters)  et al.

ALISTIPES PUTREDINIS IS A KEY SPECIES OF FECAL MICROBIOTA TRANSPLANTATION FOR ULCERATIVE COLITIS
ALISTIPES PUTREDINIS IS A KEY SPECIES OF FECAL MICROBIOTA TRANSPLANTATION FOR ULCERATIVE COLITIS

PP 05 IBD (Posters)  et al.

INFLIXIMAB BIOSIMILAR SWITCH IS SAFE AND EFFECTIVE, IT DOES NOT HAVE MAJOR PSYCHOLOGICAL IMPLICATIONS AND DOES NOT AFFET PHARMACOKINETICS IN A LARGE COHORT OF PATIENTS WITH IBD
INFLIXIMAB BIOSIMILAR SWITCH IS SAFE AND EFFECTIVE, IT DOES NOT HAVE MAJOR PSYCHOLOGICAL IMPLICATIONS AND DOES NOT AFFET PHARMACOKINETICS IN A LARGE COHORT OF PATIENTS WITH IBD

PP 05 IBD (Posters)  et al.

THE COMPARATIVE EFFECTIVENESS OF VEDOLIZUMAB AND TNF INHIBITORS IN BIO-NAÏVE PATIENTS WITH IBD: RESULTS FROM A REAL-WORLD EXPERIENCE AT A BELGIAN TERTIARY CENTRE
THE COMPARATIVE EFFECTIVENESS OF VEDOLIZUMAB AND TNF INHIBITORS IN BIO-NAÏVE PATIENTS WITH IBD: RESULTS FROM A REAL-WORLD EXPERIENCE AT A BELGIAN TERTIARY CENTRE

PP 05 IBD (Posters)  et al.

ACHIEVEMENT OF LONG-TERM TREATMENT GOALS WITH UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF INDUCTION AND MAINTENANCE PHASE 3 TRIALS
ACHIEVEMENT OF LONG-TERM TREATMENT GOALS WITH UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF INDUCTION AND MAINTENANCE PHASE 3 TRIALS

PP 05 IBD (Posters)  et al.

INCREASED RISK OF CIRRHOSIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A DANISH REGISTRY-BASED COHORT STUDY (1998-2018)
INCREASED RISK OF CIRRHOSIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A DANISH REGISTRY-BASED COHORT STUDY (1998-2018)

PP 05 IBD (Posters)  et al.

CORRELATION OF THE IBD DISK WITH INTESTINAL ULTRASOUND IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
CORRELATION OF THE IBD DISK WITH INTESTINAL ULTRASOUND IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

PP 05 IBD (Posters)  et al.

MANAGEMENT AND OUTCOME OF CYTOMEGALOVIRUS INFECTION IN ULCERATIVE COLITIS PATIENTS
MANAGEMENT AND OUTCOME OF CYTOMEGALOVIRUS INFECTION IN ULCERATIVE COLITIS PATIENTS

PP 05 IBD (Posters)  et al.

FILGOTINIB FOR THE TREATMENT OF MODERATE TO SEVERE ULCERATIVE COLITIS: AN EARLY REAL-WORLD UK TERTIARY CENTRE EXPERIENCE
FILGOTINIB FOR THE TREATMENT OF MODERATE TO SEVERE ULCERATIVE COLITIS: AN EARLY REAL-WORLD UK TERTIARY CENTRE EXPERIENCE

PP 05 IBD (Posters)  et al.

SERUM PROTEIN PROFILES DIFFER WITH USTEKINUMAB AND ADALIMUMAB TREATMENT IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
SERUM PROTEIN PROFILES DIFFER WITH USTEKINUMAB AND ADALIMUMAB TREATMENT IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

PP 05 IBD (Posters)  et al.

TRYPTOPHAN METABOLITES DYNAMICALLY ASSOCIATE WITH FATIGUE ALLEVIATION IN IBD
TRYPTOPHAN METABOLITES DYNAMICALLY ASSOCIATE WITH FATIGUE ALLEVIATION IN IBD

PP 05 IBD (Posters)  et al.

IRON-DEFICIENCY REFRACTORY ANEMIA (IDRA) IN SARDINIAN INFLAMMATORY BOWEL DISEASE PATIENTS: A LONGITUDINAL OBSERVATIONAL STUDY
IRON-DEFICIENCY REFRACTORY ANEMIA (IDRA) IN SARDINIAN INFLAMMATORY BOWEL DISEASE PATIENTS: A LONGITUDINAL OBSERVATIONAL STUDY

PP 05 IBD (Posters)  et al.

EFFECTIVENESS OF PARTIAL ENTERAL NUTRITION TO TREAT ADULTS WITH CROHN’S DISEASE WHO LOST RESPONSE TO BIOLOGICAL THERAPY
EFFECTIVENESS OF PARTIAL ENTERAL NUTRITION TO TREAT ADULTS WITH CROHN’S DISEASE WHO LOST RESPONSE TO BIOLOGICAL THERAPY

PP 05 IBD (Posters)  et al.

THE COMPARATIVE EFFECTIVENESS OF ANTI-TNF IN BIO-NAÏVE AND BIO-EXPERIENCED PATIENTS WITH IBD: RESULTS FROM A REAL-WORLD EXPERIENCE AT A BELGIAN TERTIARY CENTRE
THE COMPARATIVE EFFECTIVENESS OF ANTI-TNF IN BIO-NAÏVE AND BIO-EXPERIENCED PATIENTS WITH IBD: RESULTS FROM A REAL-WORLD EXPERIENCE AT A BELGIAN TERTIARY CENTRE

PP 05 IBD (Posters)  et al.

OUTCOMES OF VEDOLIZUMAB DOSE INTENSIFICATION: RESULTS FROM AN ASIAN INFLAMMATORY BOWEL DISEASE (IBD) COHORT STUDY
OUTCOMES OF VEDOLIZUMAB DOSE INTENSIFICATION: RESULTS FROM AN ASIAN INFLAMMATORY BOWEL DISEASE (IBD) COHORT STUDY

PP 05 IBD (Posters)  et al.

SKELETAL MUSCLE DUPD1 LINKS COLITIS WITH OBESITY-ASSOCIATED METABOLIC DISEASES
SKELETAL MUSCLE DUPD1 LINKS COLITIS WITH OBESITY-ASSOCIATED METABOLIC DISEASES

PP 05 IBD (Posters)  et al.

Item 201 - 220 / 826
1 2 3 4 5 6 7 8 9 10
11
12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42